Vaccinex Inc (VCNX)

$7.1

-0.63

(-8.15%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $6.91
    $8.02
    $7.10
    downward going graph

    2.63%

    Downside

    Day's Volatility :13.84%

    Upside

    11.51%

    downward going graph
  • $4.43
    $65.98
    $7.10
    downward going graph

    37.61%

    Downside

    52 Weeks Volatility :93.29%

    Upside

    89.24%

    downward going graph

Returns

PeriodVaccinex IncIndex (Russel 2000)
3 Months
43.72%
0.0%
6 Months
-9.28%
0.0%
1 Year
-88.34%
0.0%
3 Years
-98.58%
-19.4%

Highlights

Market Capitalization
12.2M
Book Value
$0.9
Earnings Per Share (EPS)
-25.73
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-4878.85%
Return On Assets TTM
-234.19%
Return On Equity TTM
-759.09%
Revenue TTM
124.0K
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
-81.10000000000001%
Gross Profit TTM
-13.7M
EBITDA
-22.9M
Diluted Eps TTM
-25.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Vaccinex Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 1.41%

Current $7.10
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Vaccinex Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vaccinex Inc
Vaccinex Inc
12.34%
-9.28%
-88.34%
-98.58%
-99.22%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vaccinex Inc
Vaccinex Inc
NA
NA
NA
0.0
-7.59
-2.34
NA
0.9
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vaccinex Inc
Vaccinex Inc
Buy
$12.2M
-99.22%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Vaccinex Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 550.0K → -386.0K (in $), with an average decrease of 1063.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -7.06M → -3.31M (in $), with an average increase of 30.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 148.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 299.2%

Institutional Holdings

  • Armistice Capital, LLC

    9.15%
  • Point72 Asset Management, L.P.

    7.36%
  • AIGH Capital Management, LLC

    3.68%
  • Vanguard Group Inc

    0.22%
  • Morgan Stanley - Brokerage Accounts

    0.07%
  • Tower Research Capital LLC

    0.07%

Company Information

located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop

Organization
Vaccinex Inc
Employees
37
CEO
Dr. Maurice Zauderer Ph.D.
Industry
Health Technology

FAQs